Archive: Company News
T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial
– The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with MAGE-A1 positive solid tumors
– TK-8001 targets a MAGE-A1 epitope presented on HLA-A*02:01
– IMAG1NE utilizes biomarker-guided patient selection criteria to enroll those patients that have the highest potential for safe, deep, and durable responses
– MAGE-A1 is an attractive therapeutic target that is highly cancer specific and demonstrates significant consistency of expression between primary tumor and metastases
T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced it has dosed the first patient in the IMAG1NE Phase 1/2 clinical trial.
Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer
– Former Roche Head of Neuroimmunology strengthens Rewind´s neuroimmunology and neurodegeneration expertise
Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that Irene Knuesel, PhD, PD, has been appointed as the Company´s Chief Scientific Officer.
HpVac Announces New Animal Data of its Lead Compound Demonstrating Protection Against Allergic Asthma
– Major milestone for accelerating the development of HpVac-13 in allergic diseases
HpVac SA, a company developing novel preventive and therapeutic first-line therapies against allergic and inflammatory diseases, today announced new data on its lead compound HpVac-13 for the treatment and prevention of asthmatic attacks in an animal disease model of allergic asthma.
1ST Biotherapeutics, Inc., Announces Positive Phase I Data of c-Abl Inhibitor in Neurodegeneration
– Compound demonstrates excellent safety and tolerability in single ascending dose trial
– Efficient penetration of blood-brain barrier
1ST Biotherapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics in neurodegenerative diseases and immuno-oncology, announced a successful completion of its Phase I single ascending dose (SAD) study of FB-101 in healthy adult subjects. FB-101 is a c-Abl inhibitor in development for the treatment of Parkinson’s disease and other neurodegenerative indications associated with the accumulation of alpha-synuclein. The compound was evaluated in a randomized, double-blind, placebo-controlled study to assess its safety, tolerability, and pharmacokinetics.